Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Athenex Inc (ATNX)

Athenex Inc (ATNX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 938,214
  • Shares Outstanding, K 81,726
  • Annual Sales, $ 101,230 K
  • Annual Income, $ -123,750 K
  • 60-Month Beta 0.87
  • Price/Sales 9.16
  • Price/Cash Flow N/A
  • Price/Book 7.34
Trade ATNX with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.46
  • Number of Estimates 2
  • High Estimate -0.40
  • Low Estimate -0.52
  • Prior Year -0.45
  • Growth Rate Est. (year over year) -2.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.87 +4.51%
on 10/28/20
13.16 -13.68%
on 10/08/20
-0.74 (-6.12%)
since 09/30/20
3-Month
9.97 +13.94%
on 08/27/20
15.24 -25.46%
on 09/08/20
+0.46 (+4.22%)
since 07/30/20
52-Week
5.63 +101.78%
on 03/18/20
18.35 -38.09%
on 12/11/19
+0.36 (+3.27%)
since 10/30/19

Most Recent Stories

More News
Athenex, Inc. to Report Third Quarter 2020 Earnings Results on November 5, 2020

Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today...

ATNX : 11.40 (-0.70%)
Axis Therapeutics Announces Research Collaboration with PharmaEssentia for Development of TCR-T Cell Therapy in Taiwan

Axis Therapeutics Limited, a joint venture between Athenex, Inc. (NASDAQ: ATNX) and Xiangxue Life Sciences Limited ("XLifeSc"), focused on the research, development, and commercialization of T cell immunotherapy,...

ATNX : 11.40 (-0.70%)
Athenex Oncology launches Your Guide to Facing Metastatic Breast Cancer, a first-of-its-kind self-care resource for people living with metastatic breast cancer (MBC)

and , Oct. 9, 2020 /PRNewswire/ -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment...

ATNX : 11.40 (-0.70%)
Athenex Announces FDA Allowance of IND Application for TCRT-ESO-A2, a TCR-T Cell Therapy

Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today...

ATNX : 11.40 (-0.70%)
Athenex, Inc. Announces Pricing of $110 Million Public Offering of Common Stock

Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, today announced the pricing...

ATNX : 11.40 (-0.70%)
Athenex, Inc. Announces Proposed Public Offering of Common Stock

Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, today announced that it intends...

ATNX : 11.40 (-0.70%)
Quantum Leap Healthcare Collaborative and Athenex Announce the Selection of Oral Paclitaxel plus Encequidar in Combination with dostarlimab, an anti-PD-1, in the I-SPY 2 TRIAL targeting Stage 2/3 HER2+ and HER2- Breast Cancers

Athenex's oral paclitaxel plus encequidar is being evaluated in combination with GSK's dostarlimab in the neoadjuvant chemotherapy setting

ATNX : 11.40 (-0.70%)
Athenex's NDA for Breast Cancer Drug Gets Priority Review

The FDA accepts Athenex's (ATNX) NDA for oral paclitaxel and encequidar, intended to treat metastatic breast cancer, under a priority review. The FDA's verdict is awaited on Feb 28, 2021. Stock up.

QGEN : 47.45 (-0.32%)
EBS : 90.04 (-0.80%)
HZNP : 74.99 (-3.51%)
ATNX : 11.40 (-0.70%)
Athenex (ATNX) Catches Eye: Stock Jumps 9.1%

Athenex (ATNX) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

EBS : 90.04 (-0.80%)
ATNX : 11.40 (-0.70%)
Athenex Announces FDA Acceptance for Filing of U.S. NDA for Oral Paclitaxel and Encequidar in Metastatic Breast Cancer with Priority Review

FDA grants Priority Review and sets PDUFA target action date of February 28, 2021

ATNX : 11.40 (-0.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Athenex, Inc. is a clinical stage biopharmaceutical company. It engaged in the discovery and development of drugs for the treatment of cancer. The company's platform including an Oncology Innovation Platform, a Commercial Platform and a Global Supply Chain Platform. It operates primarily in Buffalo and...

See More

Key Turning Points

2nd Resistance Point 12.07
1st Resistance Point 11.78
Last Price 11.40
1st Support Level 11.12
2nd Support Level 10.75

See More

52-Week High 18.35
Fibonacci 61.8% 13.49
Fibonacci 50% 11.99
Last Price 11.40
Fibonacci 38.2% 10.49
52-Week Low 5.63

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar